Aurinia Pharmaceuticals Intrinsic Stock Value – Aurinia Pharmaceuticals Posts Record Q4 Revenue Growth, On Track for Cash Flow Positivity
January 6, 2024
☀️Trending News
Aurinia Pharmaceuticals ($NASDAQ:AUPH) (AUPH) is a biopharmaceutical company focused on the research and development of innovative therapeutics for the treatment of auto-immune diseases. Moreover, Aurinia is on track to become cash flow positive, as it projects significant revenue growth for the year. The company’s flagship drug, Voclosporin, is a novel immunosuppressant therapy for the treatment of lupus nephritis (LN). Voclosporin has received FDA approval and is projected to be a key revenue driver for Aurinia in 2021.
The company is also looking to expand its product line with the development of other treatments for LN and other auto-immune diseases, such as multiple sclerosis and rheumatoid arthritis. Aurinia has made significant strides in the past year, between its partnership with Otsuka Pharmaceuticals and its continued success in clinical trials. As the company continues to move towards cash flow positivity and further develop its product pipeline, AUPH stock is an attractive investment that could yield significant returns for shareholders.
Earnings
The total revenue of 14.67M USD was a 73.7% decrease from the previous year, while net income was 50.26M USD. Despite this, the company has seen steady growth over the past three years, with total revenue rising dramatically from 14.67M USD to 54.52M USD.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Aurinia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 158.85 | -77.19 | -48.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aurinia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -37.32 | -3.47 | 1.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aurinia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 555.01 | 163.14 | 2.73 |
Key Ratios Snapshot
Some of the financial key ratios for Aurinia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 1007.3% | – | -50.3% |
| FCF Margin | ROE | ROA |
| -24.0% | -12.7% | -9.0% |
Stock Price
Aurinia Pharmaceuticals reported record revenue growth in its fourth quarter, up by 8% from the previous year. The stock opened at $8.4 and closed at the same price on Friday, an increase of 2.3% from the previous closing price of $8.2. With the drug having gained approval in various countries, Aurinia Pharmaceuticals is poised to continue to build on this momentum going forward. Live Quote…
Analysis – Aurinia Pharmaceuticals Intrinsic Stock Value
At GoodWhale, we recently conducted an analysis of AURINIA PHARMACEUTICALS‘s wellbeing. We used our proprietary Valuation Line to calculate the fair value of AURINIA PHARMACEUTICALS share to be around $21.5. However, at the moment, AURINIA PHARMACEUTICALS’ stock is traded at $8.4, representing a 61.0% discount from its fair value. This indicates that AURINIA PHARMACEUTICALS is currently undervalued and presents a great opportunity for potential investors. More…
Peers
The company’s lead candidate, voclosporin, is a novel, potentially first-in-class immunomodulatory drug that is being investigated for the treatment of lupus nephritis and other autoimmune diseases. Aurinia is also developing an oral formulation of voclosporin for the treatment of uveitis. Pieris Pharmaceuticals Inc, Vaxart Inc, MediWound Ltd are Aurinia’s main competitors in the market.
– Pieris Pharmaceuticals Inc ($NASDAQ:PIRS)
Pieris Pharmaceuticals Inc is a publicly traded company with a market capitalization of $74.41M as of March 2022. The company has a Return on Equity of -89.14%. Pieris Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of Anticalin proteins to treat a variety of respiratory diseases, including asthma, COPD, and cystic fibrosis.
– Vaxart Inc ($NASDAQ:VXRT)
Vaxart Inc is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The company’s vaccine candidates are based on its proprietary platform, which is designed to generate vaccine candidates to target a broad range of diseases. Vaxart’s lead program is a vaccine candidate against human papillomavirus (HPV). The company is also developing vaccine candidates against influenza and norovirus.
– MediWound Ltd ($NASDAQ:MDWD)
MediWound Ltd is a global biopharmaceutical company that develops, manufactures, and markets innovative therapeutics to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. The company has a market capitalization of 56.19 million as of 2022 and a return on equity of 193.32%. MediWound was founded in 2000 and is headquartered in Yavne, Israel.
Summary
The company is also expecting to become cash flow positive in 2021 as a result of cost savings and other strategic initiatives. Investors are encouraged by the progress Aurinia has made in developing its pipeline of treatments for lupus nephritis and dry eye syndrome. With multiple late-stage clinical trials and a potential approval from the FDA, Aurinia’s stock has seen a sharp upswing in recent months. As the company continues to advance its drug development programs, investors will be watching closely to see if it continues to deliver on its promise and deliver sustainable growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
